Presentation was good I thought. Important not to get to ahead of oneself though. Opthea had a great phase two and unsuccessful phase three. PTX results phase were excellent but derived from 11 patients. Results will need repeating over many more patients. I take comfort in the fact that the expert in America is very confident with PTX-100. We should know in 9-12 months as results should be relatively clear as to whether the same outcomes were achieved in the phase 2 trail. This is when there will be a potential significant rerate. Fingers crossed.
regards,
Bill
Ann: Prescient Therapeutics - Investor Briefing, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $42.01M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.2¢ | $16.99K | 399.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 151441 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1078430 | 3 |
View Market Depth
| Last trade - 11.31am 07/08/2025 (20 minute delay) ? |
| PTX (ASX) Chart |